mAbxience and OncoPrecision Forge Strategic Partnership for Novel Cancer Treatment Development

mAbxience and OncoPrecision Strategic Collaboration for Cancer Treatment



In a significant step towards advancing cancer treatment, mAbxience, a subsidiary of Fresenius SE & Co. KGaA, has formed a strategic partnership with OncoPrecision, an innovative biotech company. This collaboration focuses on the development and production of OncoPrecision's lead antibody-drug conjugate (ADC) candidate, ONC001. The agreement encompasses investment and manufacturing, aimed at enhancing the fighting capabilities against aggressive blood cancers, particularly monocytic acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML).

Background of the Agreement



Announced on November 18, 2026, this partnership marks a pivotal moment in oncology. mAbxience's role involves the development program for the ONC001 antibody moiety, from cell line development through to producing GMP-grade materials intended for clinical trials. This innovative ADC specifically targets CD64, with the intention of eliminating leukemic monocytes and tumor-associated macrophages, thus offering hope for patients facing limited treatment options.

The urgency behind ONC001's development is underscored by the dismal survival rates associated with the indicated blood cancers, which often measure in mere months. Both companies aim to accelerate ONC001’s introduction to clinical settings, facilitating a much-needed advancement in cancer care.

Expertise and Investment



mAbxience brings to the table its deeply rooted scientific expertise and extensive experience in antibody development. The partnership will leverage mAbxience's state-of-the-art manufacturing capabilities and a strategic investment in OncoPrecision, with Jurgen Van Broeck, CEO of mAbxience, joining OncoPrecision's Board as an Observer. This collaboration is envisioned not only to enhance the ONC001 product development but also to create sustainable value for both firms involved.

José Ramón Millán, who oversees Global Portfolio at mAbxience, expressed excitement about the partnership, emphasizing its potential to drive innovation in oncology. He remarked, "We aim to accelerate ONC001's path to the clinic while creating sustainable value for both companies."

OncoPrecision’s Co-Founder and CEO, Tarek Ali Zaki, articulated the significance of having mAbxience as a partner, noting the integration of their advanced manufacturing capabilities and regulatory knowledge. This partnership aligns with their vision to provide impactful therapies to patients.

Future Outlook



As both companies collaborate on various phases of ONC001's development, expectations are mounting. Their combined expertise positions them to navigate the complexities of clinical trials more effectively, and ultimately improve patient outcomes in cancers notorious for their aggressive nature.

The introduction of ONC001 could reshape current treatment paradigms in hematological malignancies, showcasing the transformative potential of biopharmaceutical partnerships.

In summary, this strategic alliance between mAbxience and OncoPrecision emphasizes the innovative efforts being made to tackle some of the toughest challenges in cancer treatment. With the integration of advanced technology and a commitment to patient care, this partnership symbolizes hope for many battling fierce forms of cancer. As the clinical trials approach, the spotlight will be on the promising journey of ONC001 and its potential to change lives.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.